Durect corporation announces presentations in upcoming investor conferences

Cupertino, calif. , aug. 31, 2023 /prnewswire/ -- durect corporation (nasdaq: drrx), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program , will present in the following september 2023 conferences.

DRRX Ratings Summary

DRRX Quant Ranking